$IDRA Headlines Charting a bullish early-2014 outlook

New Post Public Reply Private Reply Replies (0) Message Board

Jan 31, 2014 at 1:22 PM

$IDRA Headlines

Charting a bullish early-2014 outlook 12:05 p.m. Dec. 31, 2013 - Michael Ashbaugh
Charting a bullish early-2014 outlook 11:39 a.m. Dec. 31, 2013 - Michael Ashbaugh
S&P, Nasdaq rally from major support 11:09 a.m. Dec. 16, 2013 - Michael Ashbaugh
Pfizer, Affymetrix weigh on drug stocks 2:04 p.m. July 7, 2011 - Val Brickates Kennedy
Idera tumbles 14% on drug setback 1:52 p.m. July 7, 2011 - Val Brickates Kennedy
Tuesday's biggest gaining and declining stocks 4:37 p.m. Jan. 19, 2010 - MarketWatch
Incyte, Idera move on Novartis deals 2:02 p.m. Nov. 25, 2009 - Val Brickates Kennedy
Novartis terminates pact with Idera 8:28 a.m. Nov. 25, 2009 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 4:29 p.m. Dec. 26, 2007 - MarketWatch
Idera Pharmaceuticals' president, Karr, resigns 9:08 a.m. Dec. 26, 2007 - Robert Daniel
Idera Pharma President Karr resigns, stays on board 9:03 a.m. Dec. 26, 2007 - Robert Daniel
Idera signs agonist licensing, collaboration with Merck KGaA 7:10 a.m. Dec. 19, 2007 - Sarah Turner
Idera to get up to $381 mln in milestones 7:03 a.m. Dec. 19, 2007 - Steve Goldstein
Idera, Merck KGaA agree collaboration deal 7:02 a.m. Dec. 19, 2007 - Steve Goldstein
Wednesday's biggest stock gainers and decliners 6:03 p.m. Feb. 28, 2007 - Michael Baron
Idera Pharma started at buy at Merriman Curhan Ford 8:54 a.m. Feb. 7, 2007 - Tomi Kilgore
Drug stocks slip; Nuvelo, Neopharm shares plunge on trial results 4:37 p.m. Dec. 11, 2006 - Carolyn Pritchard

Idera Pharmaceuticals: Set To Ride A 200% Gain In 2014 9:38 a.m. Today - Seeking Alpha
First Week Of IDRA March 22nd Options Trading 10:54 a.m. Jan. 23, 2014 - TheStreet.com
Perilous Reversal Watch: Idera Pharmaceuticals (IDRA) 9:47 a.m. Jan. 23, 2014 - TheStreet.com
Good Action Under the Surface 4:45 p.m. Jan. 22, 2014 - RealMoney.com
Price Action Tells the Story 2:05 p.m. Jan. 22, 2014 - RealMoney.com
Tricky and Misleading Action 10:45 a.m. Jan. 22, 2014 - RealMoney.com
Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA) 9:48 a.m. Jan. 9, 2014 - TheStreet.com
Perilous Reversal Watch: Idera Pharmaceuticals (IDRA) 3:04 p.m. Jan. 8, 2014 - TheStreet.com
Idera Pharmaceuticals Presents a Promising Opportunity 2:23 p.m. Dec. 26, 2013 - Wall St. Cheat Sheet
Friday’s Biggest Stock Losers: INSY OPK, and More 7:52 a.m. Dec. 13, 2013 - InvestorPlace.com
9 Biotechnology Stocks to Buy Now 6:00 a.m. Dec. 11, 2013 - InvestorPlace.com
10-Q: IDERA PHARMACEUTICALS, INC. 7:02 a.m. Nov. 14, 2013 - Edgar Online - (EDG = 10Q, 10K)
Biotech-Focused Baker Bros. Accumulates These 3 Stocks 8:55 a.m. Oct. 1, 2013 - Seeking Alpha
Idera Phase 2 Data Provides For Exciting Q4 2013 And Q1 2014 8:02 a.m. Sept. 25, 2013 - Seeking Alpha
Analysts: Blackstone Mortgage Gaining Traction and 3 Other Research Notes to Browse 1:37 p.m. Aug. 29, 2013 - Wall St. Cheat Sheet
Idera Enters Agreement with NCI to Evaluate Use of TLR Antagonists for Treatment of Genetically Defined Lymphomas 6:39 a.m. Aug. 29, 2013 - benzinga.com
Idera Announces Issuance of US Patent Covering IMO-8400, Lead Candidate in Phase 2 Trial 6:05 a.m. July 18, 2013 - benzinga.com
Idera Pharma to Issue Positive Phase I Trial Results on TLR Antagonist IMO-8400 5:31 a.m. June 21, 2013 - benzinga.com
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis 6:07 a.m. June 5, 2013 - benzinga.com
10-Q: IDERA PHARMACEUTICALS, INC. 6:49 a.m. May 15, 2013 - Edgar Online - (EDG = 10Q, 10K)

Idera Announces Publication of New Data Demonstrating Impact of Inhibiting TLRs 7, 8, and 9 in a Preclinical Model of Autoimmune Disease 8:01 a.m. Jan. 22, 2014 - BusinessWire - BZX
Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine 8:00 a.m. Jan. 9, 2014 - PR Newswire
Idera Expands Leadership Team and Strengthens Clinical Development Expertise in Oncology and Orphan Diseases 8:00 a.m. Jan. 9, 2014 - BusinessWire
Relocation Plans, Patient Enrollment, Management Appointments, and Price Movements - Research Report on HCA Holdings, Opko Health, Santarus, Coronado, and Idera 8:00 a.m. Dec. 31, 2013 - PR Newswire
Senior Appointments, Stock Splits, New Guidelines, Positive Results, and Clinical Trial Updates - Research Report on Receptos, MEDNAX, CombiMatrix, Anacor, and Idera 8:00 a.m. Dec. 10, 2013 - PR Newswire
Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenstrom's Macroglobulinemia 7:30 a.m. Dec. 4, 2013 - BusinessWire
Idera Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference 4:02 p.m. Nov. 25, 2013 - BusinessWire
Idera Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Corporate Update 7:45 a.m. Nov. 14, 2013 - BusinessWire
Idera Pharmaceuticals to Host Conference Call to Report Third Quarter 2013 Financial Results on Thursday, November 14, 2013 4:10 p.m. Nov. 7, 2013 - BusinessWire
Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants 3:14 p.m. Sept. 30, 2013 - BusinessWire
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants 8:09 a.m. Sept. 25, 2013 - BusinessWire
Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants 3:01 p.m. Sept. 24, 2013 - BusinessWire
Five Star Equities Issues New Research Reports on EZCH, IDRA, PSTI and UNFI 8:01 a.m. Sept. 13, 2013 - ACCESSWIRE
Idera to Provide Update on Programs at Stifel Nicolaus Healthcare Conference 11:00 a.m. Sept. 12, 2013 - BusinessWire
Idera to Present at the Stifel Nicolaus 2013 Healthcare Conference 8:25 a.m. Sept. 10, 2013 - BusinessWire
Idera Pharmaceuticals Enters into Agreement with NCI to Evaluate Use of TLR Antagonists for the Treatment of Genetically Defined Lymphomas 7:30 a.m. Aug. 29, 2013 - BusinessWire
Idera Pharmaceuticals Reports Second Quarter 2013 Financial Results and Corporate Highlights 7:00 a.m. Aug. 15, 2013 - BusinessWire
Idera Announces Issuance of US Patent Covering IMO-8400, Lead Candidate in Phase 2 Trial 7:00 a.m. July 18, 2013 - BusinessWire
Idera Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors 8:00 a.m. July 10, 2013 - BusinessWire
Idera Pharmaceuticals Announces Results of Phase 1 Clinical Trial of IMO-8400, Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases 7:00 a.m. July 1, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

The Chemical Industry and EPA: A Broken System?

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Anecdotes by Artists Brings Raw Scent Stories to Sephora

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

FutureVault's AI Agents: Transforming Financial Workflows

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

HTX's Strategic Moves in Pakistan: A Crypto Frontier

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Davos Healthcare Aims to Revolutionize Hospital Ratings

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Succession Planning in Turmoil: Only 42% Ready

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...